This firm's average rating is Strong Buy from 2 analysts. We provide trade recommendations to complement the recent
expert consensus on OncoSec Medical Inco. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of OncoSec Medical? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
Watch out for price decline
Please consider monitoring OncoSec Medical on a daily basis if you are holding a position in it. OncoSec Medical is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as OncoSec Medical stock to be traded above the $1 level to remain listed. If OncoSec Medical stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
What is happening with OncoSec Medical this year
Annual and quarterly reports issued by OncoSec Medical are formal
financial statements that are published yearly and quarterly and sent to OncoSec stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as OncoSec Medical often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Is OncoSec Medical valued wisely by the market?
Earning per share calculations of the stock is based on official Zacks consensus of 1 analysts regarding OncoSec Medical future annual earnings. Given the historical accuracy of 68.76%, the future earnings per share of OncoSec is estimated to be -2.84 with the lowest and highest values of -2.84 and -2.84, respectively. Please note that this consensus of annual earnings estimates for the organization is an estimate of EPS before non-recurring items and including employee stock options expenses.
Is OncoSec a risky opportunity?
Let's check the volatility. OncoSec (ONCS) looks slightly risky at this time. Whether you invest your money or manage funds of your clients, remember that it is easy to forget that behind OncoSec (ONCS) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. Buying a share of a OncoSec Medical Incorporated stock makes you a part-owner of that company.
OncoSec Medical Incorporated Current Consensus
Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering OncoSec Medical Inco. The OncoSec consensus assessment is calculated by taking the average estimates from all of the analysts covering OncoSec Medical
| Strong Buy | 2 | 100.0 |
| Buy | 0 | 0.0 |
| Hold | 0 | 0.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Our take on today OncoSec Medical spike
Latest mean deviation is at 4.83. OncoSec Medical Incorporated is displaying above-average volatility over the selected time horizon. Investors should scrutinize OncoSec Medical Incorporated independently to ensure intended market timing strategies are aligned with expectations about OncoSec Medical volatility.
Our Final Take On OncoSec Medical
While other companies within the biotechnology industry are still a little expensive, even after the recent corrections, OncoSec Medical may offer a potential longer-term growth to retail investors. All things considered, as of 18th of July 2020, our primary 30 days buy-hold-sell advice on the enterprise is
Hold. We believe OncoSec Medical is
undervalued with
quite high probability of distress for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of OncoSec Medical. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
